

REMARKS/ARGUMENTS

Claims 9, 17, 29, and 46 are active.

The Examiner has allowed the compounds in Claims 9, 17 and 29.

Claim 46 is added to provide a pharmaceutical composition like allowed Claim 17 but including the specific compound of allowed Claim 29.

No new matter is added.

To the enablement rejection of Claims 30-35, 38, and 42-45, these claims have been cancelled and as such withdrawal of the rejection is requested.

A Notice of Allowance is kindly requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon



Daniel J. Pereira, Ph.D.
Registration No. 45,518

Customer Number
22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 08/03)